Human mesenchymal stromal cells (MSCs) reduce neointimal hyperplasia in a mouse model of flow-restriction by transient suppression of anti-inflammatory cytokines

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 6, 2011, Pages 464-474

  Shoji, Makoto ^a,b   Oskowitz, Adam ^a   Malone, Christopher D ^a   Prockop, Darwin J ^a,c   Pochampally, Radhika ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Biomarker; Cellular engraftment; MCP 1; Mesenchymal stem cells; Stem progenitor cells

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; BONE MARROW CELL; CAROTID ARTERY LIGATION; CELL INFILTRATION; CELL TRANSPLANTATION; HEART LEFT VENTRICLE; HUMAN; HUMAN CELL; LIPID DIET; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; STROMA CELL; VASCULAR LESION;

ALU ELEMENTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CAROTID ARTERIES; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERPLASIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; NEOINTIMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; VASCULAR SYSTEM INJURIES;

EID: 79959818451     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.6213     Document Type: Article

References (38)

1. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med, 1999; 340: 115-126
2. Kasai T, Miyauchi K, Yokoyama T, Kajimoto K, Sumiyoshi K, Kubota N, Ikeda E, Daida H: Pioglitazone attenuates neointimal thickening via suppression of early inflammatory response in a porcine coronary after stenting. Atherosclerosis, 2008; 197: 612-619
3. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S: An update on the role of markers of inflammation in atherosclerosis J Atheroscler Thromb, 2010; 17: 1-11
4. Prockop DJ: Marrow strome cells as stem cells for nonhematopoietic tissues. Science, 1997; 276: 71-74
5. Fiedler J, Leucht F, Waltenberger J, Dehio C, Brenner RE: VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. Biochem Biophys Res Commun, 2005; 334: 561-568
6. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y: Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2008; 2: 141-150
7. Uccelli A, Pistoia V, Moretta L: Mesenchymal stem cells: A new strategy for immunosuppression? Trends Immunol, 2007; 28: 219-226
8. Mirza A, Hyvelin JM, Rochefort GY, Lermusiaux P, Antier D, Awede B, Bonnet P, Domenech J, Eder V: Undifferentiated mesenchymal stem cells seeded on vascular prosthesis contribute to the restoration of a physiologic vascular wall. J Vasc Surg, 2008; 47: 1313-1321
9. Prockop DJ, Gregory CA, Spees JL: One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA, 2003; 100 (Suppl.): 11917-11923
10. Hashi CK, Zhu Y, Yang GY, Young WL, Hsiao BS, Wang K, Chu B, Li S: Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci USA, 2007; 104: 11915-11920
11. Wu X, Huang L, Zhou Q, Song Y, Li A, Jin J, Cui B: Mesenchymal stem cells participating in ex vivo endothelium repair and its effect on vascular smooth muscle cells growth. Int J Cardiol, 2005; 105: 274-282
12. Chen XC, Shan HW, Qu HL, Ge JB, Ge ZP: Bone marrow mesenchymal stem cells transplantation aggravates postangioplasty aortic restenosis in rats. Zhonghua Xin Xue Guan Bin Za Zhi, 2007; 35: 802-806
13. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ: Expansion of human adult cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells, 2002; 20: 530-554
14. Sata M, Walsh K: Fas ligand-deficient mice display enhanced leukocyte infiltration and intima hyperplasia in flow-restricted vessels. J Mol Cell Cardiol, 2000; 32: 1395-1400
15. Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J, Delafontaine P: IGF-1 reduces inflammatory responses, suppresses oxidant stress, and decreases atherosclerosis progression in ApoE deficient mice. Arterioscler Thromb Vasc Biol, 2007; 27: 2684-2690
16. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med, 2002; 8: 403-409
17. Shoji M, Iso Y, Kusuyama T, Omori Y, Soda T, Tsunoda F, Sato T, Koba S, Geshi E, Kobayashi Y, Katagiri T, Suzuki H: High-dose granulocyte colony stimulating factor promotes neointimal hyperplasia in the early phase and inhibits neoinimal hyperplasia in the late phase after vascular injury. Circ J, 2008; 72: 1885-1893
18. Sato T, Suzuki H, Shibata M, Kusuyama T, Omori Y, Soda T, Shoji M, Iso Y, Koba S, Geshi E, Katagiri T, Shioda S, Sekikawa K: Tumor-necrosis-factor-alpha-genedeficient mice have improved cardiac function through reduction of intercellular adhesion molecule-1 in myocardial infarction. Circ J, 2006; 70: 1635-1642
19. McBride C, Gaupp D, Phinney DG: Quantifying levels of transplanted murine and human mesenchymal stem cells in vivo by real-time PCR. Cytotherapy, 2003; 5: 7-18
20. Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, Prockop DJ: Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraft. Biochem Biophys Res Commun, 2007; 354: 700-706
21. Prockop DJ: "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). ClinPharmacol Ther, 2007; 82: 241-243
22. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C: Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol, 2007; 292: F1626F1635
23. Uccelli A, Pistoia V, Moretta L: Mesenchymal stem cells in health and disease. Nat Rev Immunol, 2008; 8: 726-736
24. Chen FH, Tuan RS: Mesenchymal stem cells in arthritic disease. Arthritis Res Ther, 2008; 10: 223
25. Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, Shioda S, Prockop DJ: Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA, 2008; 105: 14638-14643
26. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI: The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs, 2001; 169: 12-20
27. Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J, Prockop DJ: The CD34-like protein PODXL and alpha6integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted in mice. Blood, 2009; 113: 816-826
28. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP: Stem cell transplantation: the lung barrier. Transplant Proc, 2007; 39: 573-576
29. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ: Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA, 2006; 103: 17438-17443
30. Ohtani K, Usui M, Nakano K, Kohjimoto Y, Kitajima S, Hirouchi Y, Li XH, Kitamoto S, Takeshita A, Egashira K: Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther, 2004; 11: 1273-1282
31. Wang X, Li X, Yue TL, Ohlstein EH: Expression of monocyte chemostactic protein-3 mRNA in rat vascular smooth muscle cells and in carotid artery after balloon angioplasty. Biochim Biophys Acta, 2000; 1500: 41-48
32. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cells responses. Blood, 2005; 105: 1815-1822
33. Le Blanc K, Ringden O: Immunomodulation by mesenchymal stem cells and clincal experience. J Inter Med, 2007; 262: 509-525
34. Serhan CN, Chiang N, Van Dyke TE: Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators Nat Rev Immnunol, 2008; 8: 349-361
35. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol, 2007; 179: 1855-1863
36. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG: Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Sci USA, 2008; 104: 11002-11007
37. Marrony S, Bassilana F, Seuwen K, Keller H: Bone morphogenetic protein 2 induces placental growth factor in mesenchymal stem cells. Bone, 2003; 33: 426-433
38. Wang CH, Cherng WJ, Yang NI, Kuo LT, Hsu CM, Yeh HI, Lan YJ, Yeh CH, Stanford WL: Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol, 2008; 28: 54-60